JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

Summary

This study is an open-label, multicenter, first-in-human, Phase I/II (dose escalation and dose expansion) study to evaluate the safety, tolerability, PK, immunogenicity and efficacy of JSKN033 in patients with advanced unresectable or metastatic solid malignant tumors that are expected to be HER2 expression (IHC ≥ 1+).

Timeline

Start

2024-01-18

Primary completion

2025-07-31

Completion

2025-07-31

Outcome

Outcome not reported

Stopped (Business): “the decision is based on a strategic realignment of our clinical trial priorities to optimize the overall development pathway for JSKN033”

Drugs

Indications